Carlos Grijalva, MD, MPH

Professor, Health Policy
Vanderbilt University Medical Center, TN, United States

AHRQ (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Campbell Alliance/Syneos Health (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)CDC (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)FDA (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Merck (Consultant/Advisory Board)NIH (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Pfizer (Consultant/Advisory Board)Sanofi (Consultant/Advisory Board)Sanofi-Pasteur (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Analytic Methods for Elucidating Continuous Dose-response Associations in the Presence of Spike-effects: Avoiding the Illusion of a Safe Dose

  Friday, August 26, 2022
  2:30 PM – 2:45 PM CEST

• Identifying Acute Neuropsychiatric Events in Children and Adolescents

  Friday, August 26, 2022
  5:30 PM – 5:45 PM CEST

• Estimating the Association Between Initial Postpartum Discharge Opioid Prescription Dose and Subsequent Opioid Use: The Role of Different Modeling Strategies

  Sunday, August 28, 2022
  9:00 AM – 10:00 AM CEST